Denali Therapeutics stock reaction in context

Denali Therapeutics (DNLI) has drawn fresh attention after recent trading, with the stock closing at US$24.20 on 23 August 2026. Investors are weighing this move against the company’s biotech pipeline and current financial profile.

Despite the 1-day share price return declining 2.89% to US$24.20, Denali Therapeutics has seen momentum build recently, with a 30-day share price return of 4.72% and a year-to-date share price return of 48.74%, while the 1-year total shareholder return sits at 55.43%.

If you are interested in other opportunities around healthcare and neurology themes, it can be useful to compare Denali Therapeutics with a wider set of healthcare AI stocks using the 40 healthcare AI stocks.

After Denali Therapeutics’ recent move to US$24.20, the gap against analyst targets and intrinsic value estimates is hard to ignore. Does the share price already reflect the risk in the pipeline, or is the discount wider than justified?

Most Popular Narrative: 31.7% Undervalued

Denali Therapeutics is trading at $24.20 compared with a most followed narrative fair value of $35.44. That gap reflects some ambitious expectations around the neurology pipeline.

The enzyme transport vehicle franchise targets multiple lysosomal storage disorders where biologics are already an accepted treatment class. Denali Therapeutics expects each program to represent several hundred million dollars or more in potential annual market opportunity, which can influence long term revenue diversification and earnings resilience.

Want to see what sits behind that revenue ambition for Denali Therapeutics? The narrative leans heavily on rapid top line expansion, margin repair and a rich future earnings multiple.

Result: Fair Value of $35.44 (UNDERVALUED)

However, the Denali Therapeutics story can shift quickly if AVLAYAH uptake slows in a small Hunter syndrome pool, or if the Alzheimer’s programs stumble on timing or data.

Another view on Denali Therapeutics valuation

While the most followed narrative sees Denali Therapeutics as 31.7% undervalued at $24.20 versus a $35.44 fair value, the SWS DCF model points in the opposite direction. On that cash flow view, the stock trades well above an estimated value of $3.71, which raises a simple question for investors: Which set of assumptions feels more realistic for the next decade?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Denali Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

This mix of optimism and concern around Denali Therapeutics will mean different things to different investors. It makes sense to review the data now and decide where you stand in light of the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Denali Therapeutics?

If Denali Therapeutics has sharpened your focus on opportunities, now is the time to widen your search and avoid missing other stocks that could suit your strategy.

• Spot potential turnaround opportunities early by reviewing 23 elite penny stocks with strong financials that already show stronger financial profiles than many peers.
• Hunt for quality at a reasonable price by checking the 49 high quality undervalued stocks that combine solid fundamentals with more modest expectations.
• Prioritise resilience in your portfolio by assessing the 74 resilient stocks with low risk scores that score well on financial strength and business risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.